mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib

Treatment options for advanced metastatic thyroid cancer patients are limited. Vemurafenib, a BRAFV600E inhibitor, has shown promise in clinical trials although cellular resistance occurs. Combination therapy that includes BRAFV600E inhibition and avoids resistance is a clinical need. We used an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanly, Elyse K., Bednarczyk, Robert B., Tuli, Neha Y., Moscatello, Augustine L., Halicka, H. Dorota, Li, Jiangwei, Geliebter, Jan, Darzynkiewicz, Zbigniew, Tiwari, Raj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741856/
https://www.ncbi.nlm.nih.gov/pubmed/26284586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741856/
https://www.ncbi.nlm.nih.gov/pubmed/26284586

Ejemplares similares